SB-271,046

SB-271,046
(IUPAC) ime
	5-hloro-N-(4-metoksi-3-piperazin-1-ilfenil)-3-metil-1-benzotiofen-2-sulfonamid
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	5312149
ChEMBL	CHEMBL431298
Hemijski podaci
Formula	C20H22ClN3O3S2
Mol. masa	451,989 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C20H22ClN3O3S2/c1-13-16-11-14(21)3-6-19(16)28-20(13)29(25,26)23-15-4-5-18(27-2)17(12-15)24-9-7-22-8-10-24/h3-6,11-12,22-23H,7-10H2,1-2H3 ; Key: LOCQRDBFWSXQQI-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

SB-271,046 je lek koji se koristi u naučnim istraživanjima. On je bio jedan od prvih selektivnih antagonista 5-HT₆ receptora.^[4] SB-271,046 je potentan i selektivan in vitro i dobrom oralnom biodostupnošću in vivo, ali ima slabu penetraciju kroz krvno moždanu barijeru, te su razvijeni poboljšani 5-HT₆ antagonisti kao što su SB-357,134 i SB-399,885.^[5]

SB-271,046 povišava nivoe ekscitatornih aminokiselinskih neurotransmitera glutamata i aspartata,^[6] kao i dopamina i noradrenalina^[7] u frontalnom korteksu i hipokampusu pacova.^[8] Pokazano je da 5-HT₆ antagonisti proizvode nootropne efekte u brojnim studijama na životinjama.^[9]^[10]^[11] Smatrase da ovaj lekovi ove klase mogu da nađu primenu u tretmanu šizofrenije i drugih psihijatrijskih poremećaja.^[12]^[13]^[14]^[15]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Bromidge, SM; Brown, AM; Clarke, SE; Dodgson, K; Gager, T; Grassam, HL; Jeffrey, PM; Joiner, GF i dr.. (1999). „5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist”. Journal of Medical Chemistry 42 (2): 202–5. DOI:10.1021/jm980532e. PMID 9925723.
↑ Ahmed, M; Briggs, MA; Bromidge, SM; Buck, T; Campbell, L; Deeks, NJ; Garner, A; Gordon, L i dr.. (2005). „Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists”. Bioorganic & Medicinal Chemistry Letters 15 (21): 4867–71. DOI:10.1016/j.bmcl.2005.06.107. PMID 16143522.
↑ Dawson, LA; Nguyen, HQ; Li, P (2000). „In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate”. British Journal of Pharmacology 130 (1): 23–6. DOI:10.1038/sj.bjp.0703288. PMC 1572041. PMID 10780993.
↑ Lacroix, LP; Dawson, LA; Hagan, JJ; Heidbreder, CA (2004). „5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex”. Synapse 51 (2): 158–64. DOI:10.1002/syn.10288. PMID 14618683.
↑ Dawson, LA; Nguyen, HQ; Li, P (2001). „The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus”. Neuropsychopharmacology 25 (5): 662–8. DOI:10.1016/S0893-133X(01)00265-2. PMID 11682249.
↑ Rogers, DC; Hagan, JJ (2001). „5-HT6 receptor antagonists enhance retention of a water maze task in the rat”. Psychopharmacology 158 (2): 114–9. DOI:10.1007/s002130100840. PMID 11702084.
↑ Foley, AG; Murphy, KJ; Hirst, WD; Gallagher, HC; Hagan, JJ; Upton, N; Walsh, FS; Regan, CM (2004). „The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats”. Neuropsychopharmacology 29 (1): 93–100. DOI:10.1038/sj.npp.1300332. PMID 14571256.
↑ Marcos, B; Chuang, TT; Gil-Bea, FJ; Ramirez, MJ (2008). „Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat”. British Journal of Pharmacology 155 (3): 434–40. DOI:10.1038/bjp.2008.281. PMC 2567877. PMID 18622410.
↑ Minabe, Y; Shirayama, Y; Hashimoto, K; Routledge, C; Hagan, JJ; Ashby Jr, CR (2004). „Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study”. Synapse 52 (1): 20–8. DOI:10.1002/syn.20002. PMID 14755629.
↑ De Foubert, G; O'Neill, MJ; Zetterström, TS (2007). „Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression”. Neuroscience 147 (3): 778–85. DOI:10.1016/j.neuroscience.2007.04.045. PMID 17560041.
↑ Marcos, B; Aisa, B; Ramírez, MJ (2008). „Functional interaction between 5-HT(6) receptors and hypothalamic-pituitary-adrenal axis: cognitive implications”. Neuropharmacology 54 (4): 708–14. DOI:10.1016/j.neuropharm.2007.11.019. PMID 18206183.
↑ Loiseau, F; Dekeyne, A; Millan, MJ (2008). „Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex”. Psychopharmacology 196 (1): 93–104. DOI:10.1007/s00213-007-0934-5. PMID 17922111.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] Bromidge, SM; Brown, AM; Clarke, SE; Dodgson, K; Gager, T; Grassam, HL; Jeffrey, PM; Joiner, GF i dr.. (1999). „5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist”. Journal of Medical Chemistry 42 (2): 202–5. DOI:10.1021/jm980532e. PMID 9925723.

[5] Ahmed, M; Briggs, MA; Bromidge, SM; Buck, T; Campbell, L; Deeks, NJ; Garner, A; Gordon, L i dr.. (2005). „Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists”. Bioorganic & Medicinal Chemistry Letters 15 (21): 4867–71. DOI:10.1016/j.bmcl.2005.06.107. PMID 16143522.

[6] Dawson, LA; Nguyen, HQ; Li, P (2000). „In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate”. British Journal of Pharmacology 130 (1): 23–6. DOI:10.1038/sj.bjp.0703288. PMC 1572041. PMID 10780993.

[7] Lacroix, LP; Dawson, LA; Hagan, JJ; Heidbreder, CA (2004). „5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex”. Synapse 51 (2): 158–64. DOI:10.1002/syn.10288. PMID 14618683.

[8] Dawson, LA; Nguyen, HQ; Li, P (2001). „The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus”. Neuropsychopharmacology 25 (5): 662–8. DOI:10.1016/S0893-133X(01)00265-2. PMID 11682249.

[9] Rogers, DC; Hagan, JJ (2001). „5-HT6 receptor antagonists enhance retention of a water maze task in the rat”. Psychopharmacology 158 (2): 114–9. DOI:10.1007/s002130100840. PMID 11702084.

[10] Foley, AG; Murphy, KJ; Hirst, WD; Gallagher, HC; Hagan, JJ; Upton, N; Walsh, FS; Regan, CM (2004). „The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats”. Neuropsychopharmacology 29 (1): 93–100. DOI:10.1038/sj.npp.1300332. PMID 14571256.

[11] Marcos, B; Chuang, TT; Gil-Bea, FJ; Ramirez, MJ (2008). „Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat”. British Journal of Pharmacology 155 (3): 434–40. DOI:10.1038/bjp.2008.281. PMC 2567877. PMID 18622410.

[12] Minabe, Y; Shirayama, Y; Hashimoto, K; Routledge, C; Hagan, JJ; Ashby Jr, CR (2004). „Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study”. Synapse 52 (1): 20–8. DOI:10.1002/syn.20002. PMID 14755629.

[13] De Foubert, G; O'Neill, MJ; Zetterström, TS (2007). „Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression”. Neuroscience 147 (3): 778–85. DOI:10.1016/j.neuroscience.2007.04.045. PMID 17560041.

[14] Marcos, B; Aisa, B; Ramírez, MJ (2008). „Functional interaction between 5-HT(6) receptors and hypothalamic-pituitary-adrenal axis: cognitive implications”. Neuropharmacology 54 (4): 708–14. DOI:10.1016/j.neuropharm.2007.11.019. PMID 18206183.

[15] Loiseau, F; Dekeyne, A; Millan, MJ (2008). „Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex”. Psychopharmacology 196 (1): 93–104. DOI:10.1007/s00213-007-0934-5. PMID 17922111.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]